Lefitolimod

Drug Profile

Lefitolimod

Alternative Names: MGN-1703

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Mologen
  • Developer Aarhus Universitetshospital; Mologen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; DNA
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Small cell lung cancer
  • Phase I/II HIV-1 infections
  • Phase I Solid tumours

Most Recent Events

  • 10 Jan 2017 Mologen AG plans a clinical trial for HIV-1 infections (Combination therapy)
  • 11 May 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (SC) (NCT02668770)
  • 18 Sep 2015 No recent reports on development identified - Phase-II for Colorectal cancer (First-line therapy) in Russia and Czech Republic (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top